Biosecurity Modernization and Innovation Act of 2026
Senate Bill Would Require Mandatory Screening of Synthetic DNA Orders to Block Bioweapon Risk
Legislative Progress
Key Points
- This bill requires companies that sell synthetic DNA or DNA-making machines to screen every order. They must check if the DNA sequences being ordered match a list of 'sequences of concern' that could be used to create dangerous viruses or bacteria.
- The policy affects biotechnology companies, researchers, and universities. Any person or group receiving federal funding would be banned from buying synthetic DNA from companies that do not follow these new security rules.
- As DNA technology gets cheaper and faster, there is a growing risk that bad actors could order the building blocks for a new pandemic. This policy aims to replace voluntary guidelines with mandatory rules to make sure no one can secretly buy the parts for a bioweapon.
- The government would use 'red-teaming'—sending fake suspicious orders—to test if companies are actually doing the screening. Companies that fail to follow the rules could face fines of up to $750,000 per violation.
- To keep from slowing down legitimate science, the bill allows for 'fast-track' reviews for trusted institutions like universities. It also creates a 'sandbox' where new security tools can be tested without stopping regular research.
Impact Analysis
Personal Impact
Small biotech companies that synthesize or sell synthetic DNA would face new mandatory screening requirements for every order and customer. They'd need to invest in compliance infrastructure, undergo regular audits and surprise 'red-team' testing, and risk fines up to $750,000 for violations. However, the bill includes exemptions for clearly non-hazardous sequences and expedited reviews for trusted institutional customers, which should reduce some burden. Smaller firms may struggle more with compliance costs compared to large companies that already do voluntary screening.
Milestones
Read twice and referred to the Committee on Commerce, Science, and Transportation.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Related News
2 articles
Tech bills of the week: Restricting biometric use; expanding the quantum workforce; and more
The Biosecurity Modernization and Innovation Act, introduced by Sens. Klobuchar and Cotton, targets the misuse of gene synthesis technology by directing providers to screen orders for lethal pathogens and asking NIST to develop safety standards and best practices for the biotech sector.
Governing Biotechnology’s Dual-Use Security Dilemma – Analysis
The US introduced the Biosecurity Modernization and Innovation Act to broaden the national biosecurity framework, taking cognisance of rapid advancements in the field and the risk of losing leadership to foreign adversaries while addressing the dual-use security dilemma in biotech.
Source Information
Document Type
Congressional Bill
Official Title
Biosecurity Modernization and Innovation Act of 2026
Data Sources
Sponsor
Cosponsors
(1)Analysis generated by AI. Always verify with official sources.